It becomes a disease Multiple myeloma survival rate 2015, a hematological cancer for which there is no cure, chronic is a matter of time. At least so believe specialists. And guarantee you some of the results they are getting with new drugs, that they manage to increase the survival of patients who do not respond to other treatments in nearly three years.
The last of these is lenalidomide, an immunomodulator that swallowed, but before had already reached others, such as bortezomib and Thalidomide. All these molecules act differently on this cancer of the blood and become complementary treatments.
Multiple myeloma is a cancer that affects plasma cells in the blood. Each year, around 22,000 Americans are diagnosed with multiple myeloma, according to the American Cancer Society.
The power of five years for multiple myeloma survival rate is only 40 percent. However, recent advances it is likely to increase the survival rate for people who are diagnosed in the future, according to the cancer society.
Combination therapy of lenalidomide and dexamethasone improved in multiple myeloma progression-free survival in the year 2012.
A study compared the SLP in newly diagnosed multiple myeloma patients that this therapy was administered with the results obtained with the regime of melphalan, prednisone and Thalidomide.
The combined treatment of oral lenalidomide and dexamethasone in low doses (Rd) improved statistically significantly in newly diagnosed patients with multiple myeloma (SLP) progression-free survival. Thus confirms it phase III MM-020/IFM 07-01 with REVLIMID ® (lenalidomide), which has achieved its primary objective by comparing outcomes in patients who are administered this therapy combined with those obtained in those who received a triple system of treatment based on melphalan, prednisone and Thalidomide (MPT).
The randomized study of MM-020/IFM 07-01, also known as FIRST (Front-Line Investigation of Revlimid / Dexamethasone vs.) Standard Thalidomide), is one of the largest international studies in phase III of research developed in newly diagnosed patients with multiple myeloma.
For its realization, was assessed a sample of 1,623 patients who were not candidates for autologous transplantation of stem cells that were continuously oral lenalidomide and dexamethasone in low doses until disease progression; lenalidomide and dexamethasone in low doses during 18 cycles of 28 days (72 weeks); melphalan, prednisone and Thalidomide for a maximum of twelve cycles of 42 days (72 weeks), with the aim of evaluating the SLP in different treatment arms.
On the other hand, the secondary objectives of the research the overall survival, response rate, quality of life and security include. The study of safety and efficacy is still in development and expected that the results will occur soon.
Celgene will initiate discussions with the regulatory authorities and expected to submit the information required for registration in the United States, Europe and other markets. These results come from a research study in phase III development. Currently, lenalidomide is not approved in newly diagnosed multiple myeloma patients in any country.